NCT06279247 Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
| NCT ID | NCT06279247 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qilu Hospital of Shandong University |
| Condition | Narcolepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2026-08-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2022-09-01 with a primary completion date of 2026-08-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed. At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy.
Eligibility Criteria
Inclusion Criteria * All patients met the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3). Exclusion Criteria * primary hypersomnia or hypersomnia due to shift work, sleep deprivation and other sleep rhythm disturbances; * excessive sleep due to drug abuse; * suffering from Parkinson's disease, Alzheimer's disease and other nervous system diseases and mental diseases; * complicated with heart, lung, liver, kidney, blood endocrine system and other basic diseases, or acute chronic infection in a short period of time; * Use of sedatives, hypnotics, antidepressants, lithium and dopamine receptor antagonists for two weeks before examination; * patients who cannot cooperate with PSG and MSLT due to various factors.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06279247 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 100 Years, studying Narcolepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06279247 currently recruiting?
Yes, NCT06279247 is actively recruiting participants. Contact the research team at haiyunli1122@163.com for enrollment information.
Where is the NCT06279247 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06279247 clinical trial?
NCT06279247 is sponsored by Qilu Hospital of Shandong University. The trial plans to enroll 60 participants.